nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Etoposide—testicular cancer	0.227	0.43	CiPCiCtD
Topotecan—ovarian cancer—testicular cancer	0.168	0.553	CtDrD
Topotecan—Topoisomerase Inhibitors—Epirubicin—testicular cancer	0.156	0.296	CiPCiCtD
Topotecan—Topoisomerase Inhibitors—Doxorubicin—testicular cancer	0.144	0.274	CiPCiCtD
Topotecan—lung cancer—testicular cancer	0.136	0.447	CtDrD
Topotecan—ABCG2—Dactinomycin—testicular cancer	0.0214	0.184	CbGbCtD
Topotecan—ABCG2—Carboplatin—testicular cancer	0.0144	0.124	CbGbCtD
Topotecan—ABCG2—Cisplatin—testicular cancer	0.0123	0.106	CbGbCtD
Topotecan—ABCG2—Etoposide—testicular cancer	0.0121	0.104	CbGbCtD
Topotecan—ABCG2—Doxorubicin—testicular cancer	0.00823	0.0708	CbGbCtD
Topotecan—ABCG2—Methotrexate—testicular cancer	0.00797	0.0686	CbGbCtD
Topotecan—ABCB1—Dactinomycin—testicular cancer	0.00771	0.0664	CbGbCtD
Topotecan—CYP3A4—Ifosfamide—testicular cancer	0.00545	0.0469	CbGbCtD
Topotecan—ABCB1—Vinblastine—testicular cancer	0.00483	0.0416	CbGbCtD
Topotecan—ABCB1—Cisplatin—testicular cancer	0.00443	0.0381	CbGbCtD
Topotecan—ABCB1—Etoposide—testicular cancer	0.00435	0.0374	CbGbCtD
Topotecan—ABCB1—Doxorubicin—testicular cancer	0.00297	0.0255	CbGbCtD
Topotecan—CYP3A4—Vinblastine—testicular cancer	0.00289	0.0249	CbGbCtD
Topotecan—ABCB1—Methotrexate—testicular cancer	0.00287	0.0247	CbGbCtD
Topotecan—CYP3A4—Etoposide—testicular cancer	0.00261	0.0224	CbGbCtD
Topotecan—CYP3A4—Doxorubicin—testicular cancer	0.00178	0.0153	CbGbCtD
Topotecan—TOP1MT—gonad—testicular cancer	0.00111	0.165	CbGeAlD
Topotecan—TOP1MT—female gonad—testicular cancer	0.000903	0.134	CbGeAlD
Topotecan—TOP1—seminal vesicle—testicular cancer	0.000811	0.12	CbGeAlD
Topotecan—TOP1MT—testis—testicular cancer	0.000801	0.119	CbGeAlD
Topotecan—TOP1MT—lymph node—testicular cancer	0.00058	0.0862	CbGeAlD
Topotecan—TOP1—female gonad—testicular cancer	0.000476	0.0707	CbGeAlD
Topotecan—TOP1—testis—testicular cancer	0.000422	0.0627	CbGeAlD
Topotecan—TOP1—lymph node—testicular cancer	0.000306	0.0455	CbGeAlD
Topotecan—ABCG2—seminal vesicle—testicular cancer	0.000288	0.0427	CbGeAlD
Topotecan—ABCG2—female gonad—testicular cancer	0.000169	0.0251	CbGeAlD
Topotecan—ABCB1—embryo—testicular cancer	0.000151	0.0224	CbGeAlD
Topotecan—ABCG2—testis—testicular cancer	0.00015	0.0223	CbGeAlD
Topotecan—ABCB1—seminal vesicle—testicular cancer	0.000142	0.0211	CbGeAlD
Topotecan—ABCG2—lymph node—testicular cancer	0.000109	0.0161	CbGeAlD
Topotecan—ABCB1—gonad—testicular cancer	0.000102	0.0152	CbGeAlD
Topotecan—ABCB1—female gonad—testicular cancer	8.33e-05	0.0124	CbGeAlD
Topotecan—ABCB1—testis—testicular cancer	7.39e-05	0.011	CbGeAlD
Topotecan—ABCB1—lymph node—testicular cancer	5.35e-05	0.00796	CbGeAlD
Topotecan—Musculoskeletal discomfort—Cisplatin—testicular cancer	4.54e-05	0.000978	CcSEcCtD
Topotecan—Infection—Etoposide—testicular cancer	4.53e-05	0.000977	CcSEcCtD
Topotecan—Asthenia—Dactinomycin—testicular cancer	4.52e-05	0.000974	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—testicular cancer	4.49e-05	0.000968	CcSEcCtD
Topotecan—Paraesthesia—Cisplatin—testicular cancer	4.47e-05	0.000963	CcSEcCtD
Topotecan—Thrombocytopenia—Etoposide—testicular cancer	4.47e-05	0.000962	CcSEcCtD
Topotecan—Dyspnoea—Cisplatin—testicular cancer	4.44e-05	0.000957	CcSEcCtD
Topotecan—Skin disorder—Etoposide—testicular cancer	4.43e-05	0.000955	CcSEcCtD
Topotecan—Hyperhidrosis—Etoposide—testicular cancer	4.41e-05	0.00095	CcSEcCtD
Topotecan—Anorexia—Etoposide—testicular cancer	4.35e-05	0.000937	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	4.33e-05	0.000934	CcSEcCtD
Topotecan—Decreased appetite—Cisplatin—testicular cancer	4.33e-05	0.000933	CcSEcCtD
Topotecan—Diarrhoea—Dactinomycin—testicular cancer	4.31e-05	0.000929	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—testicular cancer	4.31e-05	0.000929	CcSEcCtD
Topotecan—Gastrointestinal disorder—Cisplatin—testicular cancer	4.3e-05	0.000926	CcSEcCtD
Topotecan—Vomiting—Bleomycin—testicular cancer	4.3e-05	0.000926	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—testicular cancer	4.28e-05	0.000923	CcSEcCtD
Topotecan—Infestation—Methotrexate—testicular cancer	4.28e-05	0.000923	CcSEcCtD
Topotecan—Pancytopenia—Epirubicin—testicular cancer	4.27e-05	0.00092	CcSEcCtD
Topotecan—Rash—Bleomycin—testicular cancer	4.26e-05	0.000918	CcSEcCtD
Topotecan—Pain—Cisplatin—testicular cancer	4.26e-05	0.000918	CcSEcCtD
Topotecan—Dermatitis—Bleomycin—testicular cancer	4.26e-05	0.000917	CcSEcCtD
Topotecan—Hypersensitivity—Ifosfamide—testicular cancer	4.26e-05	0.000917	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Doxorubicin—testicular cancer	4.25e-05	0.000915	CcSEcCtD
Topotecan—Neutropenia—Epirubicin—testicular cancer	4.2e-05	0.000906	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—testicular cancer	4.18e-05	0.0009	CcSEcCtD
Topotecan—Asthenia—Ifosfamide—testicular cancer	4.14e-05	0.000893	CcSEcCtD
Topotecan—Sweating—Methotrexate—testicular cancer	4.11e-05	0.000885	CcSEcCtD
Topotecan—Feeling abnormal—Cisplatin—testicular cancer	4.1e-05	0.000884	CcSEcCtD
Topotecan—Paraesthesia—Etoposide—testicular cancer	4.1e-05	0.000883	CcSEcCtD
Topotecan—Weight increased—Epirubicin—testicular cancer	4.09e-05	0.000882	CcSEcCtD
Topotecan—Pruritus—Ifosfamide—testicular cancer	4.09e-05	0.000881	CcSEcCtD
Topotecan—Dyspnoea—Etoposide—testicular cancer	4.07e-05	0.000876	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—testicular cancer	4.05e-05	0.000873	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—testicular cancer	4.04e-05	0.000871	CcSEcCtD
Topotecan—Pneumonia—Epirubicin—testicular cancer	4.03e-05	0.000869	CcSEcCtD
Topotecan—Nausea—Bleomycin—testicular cancer	4.01e-05	0.000865	CcSEcCtD
Topotecan—Infestation—Epirubicin—testicular cancer	4.01e-05	0.000864	CcSEcCtD
Topotecan—Infestation NOS—Epirubicin—testicular cancer	4.01e-05	0.000864	CcSEcCtD
Topotecan—Vomiting—Dactinomycin—testicular cancer	4.01e-05	0.000864	CcSEcCtD
Topotecan—Rash—Dactinomycin—testicular cancer	3.97e-05	0.000856	CcSEcCtD
Topotecan—Decreased appetite—Etoposide—testicular cancer	3.97e-05	0.000854	CcSEcCtD
Topotecan—Diarrhoea—Ifosfamide—testicular cancer	3.95e-05	0.000852	CcSEcCtD
Topotecan—Pancytopenia—Doxorubicin—testicular cancer	3.95e-05	0.000851	CcSEcCtD
Topotecan—Gastrointestinal disorder—Etoposide—testicular cancer	3.94e-05	0.000849	CcSEcCtD
Topotecan—Body temperature increased—Cisplatin—testicular cancer	3.94e-05	0.000848	CcSEcCtD
Topotecan—Fatigue—Etoposide—testicular cancer	3.93e-05	0.000847	CcSEcCtD
Topotecan—Neuropathy peripheral—Epirubicin—testicular cancer	3.93e-05	0.000847	CcSEcCtD
Topotecan—Stomatitis—Epirubicin—testicular cancer	3.91e-05	0.000842	CcSEcCtD
Topotecan—Constipation—Etoposide—testicular cancer	3.9e-05	0.000841	CcSEcCtD
Topotecan—Pain—Etoposide—testicular cancer	3.9e-05	0.000841	CcSEcCtD
Topotecan—Neutropenia—Doxorubicin—testicular cancer	3.89e-05	0.000838	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—testicular cancer	3.87e-05	0.000833	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—testicular cancer	3.85e-05	0.000829	CcSEcCtD
Topotecan—Sweating—Epirubicin—testicular cancer	3.84e-05	0.000828	CcSEcCtD
Topotecan—Dizziness—Ifosfamide—testicular cancer	3.82e-05	0.000823	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—testicular cancer	3.82e-05	0.000822	CcSEcCtD
Topotecan—Hepatobiliary disease—Epirubicin—testicular cancer	3.79e-05	0.000817	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—testicular cancer	3.79e-05	0.000816	CcSEcCtD
Topotecan—Epistaxis—Epirubicin—testicular cancer	3.78e-05	0.000815	CcSEcCtD
Topotecan—Feeling abnormal—Etoposide—testicular cancer	3.76e-05	0.00081	CcSEcCtD
Topotecan—Nausea—Dactinomycin—testicular cancer	3.74e-05	0.000807	CcSEcCtD
Topotecan—Pneumonia—Doxorubicin—testicular cancer	3.73e-05	0.000804	CcSEcCtD
Topotecan—Gastrointestinal pain—Etoposide—testicular cancer	3.73e-05	0.000804	CcSEcCtD
Topotecan—Infestation NOS—Doxorubicin—testicular cancer	3.71e-05	0.000799	CcSEcCtD
Topotecan—Infestation—Doxorubicin—testicular cancer	3.71e-05	0.000799	CcSEcCtD
Topotecan—Vomiting—Ifosfamide—testicular cancer	3.67e-05	0.000791	CcSEcCtD
Topotecan—Hypersensitivity—Cisplatin—testicular cancer	3.67e-05	0.00079	CcSEcCtD
Topotecan—Rash—Ifosfamide—testicular cancer	3.64e-05	0.000785	CcSEcCtD
Topotecan—Dermatitis—Ifosfamide—testicular cancer	3.64e-05	0.000784	CcSEcCtD
Topotecan—Neuropathy peripheral—Doxorubicin—testicular cancer	3.64e-05	0.000784	CcSEcCtD
Topotecan—Urticaria—Etoposide—testicular cancer	3.62e-05	0.000781	CcSEcCtD
Topotecan—Haemoglobin—Epirubicin—testicular cancer	3.62e-05	0.000779	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—testicular cancer	3.62e-05	0.000779	CcSEcCtD
Topotecan—Rhinitis—Epirubicin—testicular cancer	3.61e-05	0.000778	CcSEcCtD
Topotecan—Abdominal pain—Etoposide—testicular cancer	3.61e-05	0.000777	CcSEcCtD
Topotecan—Body temperature increased—Etoposide—testicular cancer	3.61e-05	0.000777	CcSEcCtD
Topotecan—Haemorrhage—Epirubicin—testicular cancer	3.6e-05	0.000776	CcSEcCtD
Topotecan—Hypoaesthesia—Epirubicin—testicular cancer	3.58e-05	0.000772	CcSEcCtD
Topotecan—Asthenia—Cisplatin—testicular cancer	3.57e-05	0.00077	CcSEcCtD
Topotecan—Pharyngitis—Epirubicin—testicular cancer	3.57e-05	0.00077	CcSEcCtD
Topotecan—Sweating—Doxorubicin—testicular cancer	3.56e-05	0.000766	CcSEcCtD
Topotecan—Hepatobiliary disease—Doxorubicin—testicular cancer	3.51e-05	0.000756	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—testicular cancer	3.5e-05	0.000754	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—testicular cancer	3.49e-05	0.000752	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—testicular cancer	3.47e-05	0.000749	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—testicular cancer	3.47e-05	0.000747	CcSEcCtD
Topotecan—Chills—Methotrexate—testicular cancer	3.45e-05	0.000744	CcSEcCtD
Topotecan—Nausea—Ifosfamide—testicular cancer	3.43e-05	0.000739	CcSEcCtD
Topotecan—Diarrhoea—Cisplatin—testicular cancer	3.41e-05	0.000734	CcSEcCtD
Topotecan—Alopecia—Methotrexate—testicular cancer	3.4e-05	0.000732	CcSEcCtD
Topotecan—Hypersensitivity—Etoposide—testicular cancer	3.36e-05	0.000724	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—testicular cancer	3.35e-05	0.000721	CcSEcCtD
Topotecan—Haemoglobin—Doxorubicin—testicular cancer	3.35e-05	0.000721	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—testicular cancer	3.34e-05	0.000719	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—testicular cancer	3.33e-05	0.000718	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—testicular cancer	3.31e-05	0.000714	CcSEcCtD
Topotecan—Pharyngitis—Doxorubicin—testicular cancer	3.3e-05	0.000712	CcSEcCtD
Topotecan—Asthenia—Etoposide—testicular cancer	3.27e-05	0.000705	CcSEcCtD
Topotecan—Angiopathy—Epirubicin—testicular cancer	3.27e-05	0.000704	CcSEcCtD
Topotecan—Immune system disorder—Epirubicin—testicular cancer	3.25e-05	0.0007	CcSEcCtD
Topotecan—Mediastinal disorder—Epirubicin—testicular cancer	3.24e-05	0.000699	CcSEcCtD
Topotecan—Back pain—Methotrexate—testicular cancer	3.24e-05	0.000698	CcSEcCtD
Topotecan—Chills—Epirubicin—testicular cancer	3.23e-05	0.000696	CcSEcCtD
Topotecan—Pruritus—Etoposide—testicular cancer	3.23e-05	0.000695	CcSEcCtD
Topotecan—Alopecia—Epirubicin—testicular cancer	3.18e-05	0.000685	CcSEcCtD
Topotecan—Vomiting—Cisplatin—testicular cancer	3.17e-05	0.000682	CcSEcCtD
Topotecan—Rash—Cisplatin—testicular cancer	3.14e-05	0.000676	CcSEcCtD
Topotecan—Dermatitis—Cisplatin—testicular cancer	3.14e-05	0.000676	CcSEcCtD
Topotecan—Malnutrition—Epirubicin—testicular cancer	3.13e-05	0.000675	CcSEcCtD
Topotecan—Diarrhoea—Etoposide—testicular cancer	3.12e-05	0.000673	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—testicular cancer	3.11e-05	0.000669	CcSEcCtD
Topotecan—Anaemia—Methotrexate—testicular cancer	3.09e-05	0.000667	CcSEcCtD
Topotecan—Back pain—Epirubicin—testicular cancer	3.03e-05	0.000653	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—testicular cancer	3.02e-05	0.000651	CcSEcCtD
Topotecan—Malaise—Methotrexate—testicular cancer	3.02e-05	0.000651	CcSEcCtD
Topotecan—Dizziness—Etoposide—testicular cancer	3.02e-05	0.00065	CcSEcCtD
Topotecan—Muscle spasms—Epirubicin—testicular cancer	3.01e-05	0.000649	CcSEcCtD
Topotecan—Immune system disorder—Doxorubicin—testicular cancer	3.01e-05	0.000648	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—testicular cancer	3e-05	0.000647	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—testicular cancer	3e-05	0.000646	CcSEcCtD
Topotecan—Chills—Doxorubicin—testicular cancer	2.99e-05	0.000644	CcSEcCtD
Topotecan—Nausea—Cisplatin—testicular cancer	2.96e-05	0.000637	CcSEcCtD
Topotecan—Alopecia—Doxorubicin—testicular cancer	2.94e-05	0.000634	CcSEcCtD
Topotecan—Cough—Methotrexate—testicular cancer	2.92e-05	0.00063	CcSEcCtD
Topotecan—Ill-defined disorder—Epirubicin—testicular cancer	2.91e-05	0.000626	CcSEcCtD
Topotecan—Vomiting—Etoposide—testicular cancer	2.9e-05	0.000625	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—testicular cancer	2.9e-05	0.000625	CcSEcCtD
Topotecan—Anaemia—Epirubicin—testicular cancer	2.9e-05	0.000624	CcSEcCtD
Topotecan—Rash—Etoposide—testicular cancer	2.88e-05	0.00062	CcSEcCtD
Topotecan—Dermatitis—Etoposide—testicular cancer	2.87e-05	0.000619	CcSEcCtD
Topotecan—Headache—Etoposide—testicular cancer	2.86e-05	0.000616	CcSEcCtD
Topotecan—Chest pain—Methotrexate—testicular cancer	2.85e-05	0.000614	CcSEcCtD
Topotecan—Myalgia—Methotrexate—testicular cancer	2.85e-05	0.000614	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—testicular cancer	2.85e-05	0.000614	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	2.83e-05	0.00061	CcSEcCtD
Topotecan—Malaise—Epirubicin—testicular cancer	2.83e-05	0.000609	CcSEcCtD
Topotecan—Discomfort—Methotrexate—testicular cancer	2.82e-05	0.000607	CcSEcCtD
Topotecan—Leukopenia—Epirubicin—testicular cancer	2.8e-05	0.000604	CcSEcCtD
Topotecan—Back pain—Doxorubicin—testicular cancer	2.8e-05	0.000604	CcSEcCtD
Topotecan—Muscle spasms—Doxorubicin—testicular cancer	2.79e-05	0.000601	CcSEcCtD
Topotecan—Cough—Epirubicin—testicular cancer	2.73e-05	0.000589	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—testicular cancer	2.73e-05	0.000589	CcSEcCtD
Topotecan—Infection—Methotrexate—testicular cancer	2.71e-05	0.000585	CcSEcCtD
Topotecan—Nausea—Etoposide—testicular cancer	2.71e-05	0.000584	CcSEcCtD
Topotecan—Ill-defined disorder—Doxorubicin—testicular cancer	2.69e-05	0.00058	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—testicular cancer	2.68e-05	0.000577	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—testicular cancer	2.68e-05	0.000577	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—testicular cancer	2.68e-05	0.000576	CcSEcCtD
Topotecan—Myalgia—Epirubicin—testicular cancer	2.67e-05	0.000575	CcSEcCtD
Topotecan—Arthralgia—Epirubicin—testicular cancer	2.67e-05	0.000575	CcSEcCtD
Topotecan—Chest pain—Epirubicin—testicular cancer	2.67e-05	0.000575	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—testicular cancer	2.65e-05	0.000572	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	2.65e-05	0.000571	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—testicular cancer	2.64e-05	0.000569	CcSEcCtD
Topotecan—Discomfort—Epirubicin—testicular cancer	2.64e-05	0.000568	CcSEcCtD
Topotecan—Malaise—Doxorubicin—testicular cancer	2.61e-05	0.000563	CcSEcCtD
Topotecan—Anorexia—Methotrexate—testicular cancer	2.6e-05	0.000561	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—testicular cancer	2.59e-05	0.000559	CcSEcCtD
Topotecan—Anaphylactic shock—Epirubicin—testicular cancer	2.56e-05	0.000551	CcSEcCtD
Topotecan—Infection—Epirubicin—testicular cancer	2.54e-05	0.000547	CcSEcCtD
Topotecan—Cough—Doxorubicin—testicular cancer	2.53e-05	0.000545	CcSEcCtD
Topotecan—Nervous system disorder—Epirubicin—testicular cancer	2.51e-05	0.00054	CcSEcCtD
Topotecan—Thrombocytopenia—Epirubicin—testicular cancer	2.5e-05	0.000539	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—testicular cancer	2.49e-05	0.000536	CcSEcCtD
Topotecan—Skin disorder—Epirubicin—testicular cancer	2.48e-05	0.000535	CcSEcCtD
Topotecan—Hyperhidrosis—Epirubicin—testicular cancer	2.47e-05	0.000533	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—testicular cancer	2.47e-05	0.000532	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—testicular cancer	2.47e-05	0.000532	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—testicular cancer	2.47e-05	0.000532	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—testicular cancer	2.45e-05	0.000529	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.45e-05	0.000528	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—testicular cancer	2.44e-05	0.000525	CcSEcCtD
Topotecan—Anorexia—Epirubicin—testicular cancer	2.44e-05	0.000525	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—testicular cancer	2.44e-05	0.000525	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—testicular cancer	2.41e-05	0.000518	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—testicular cancer	2.38e-05	0.000512	CcSEcCtD
Topotecan—Anaphylactic shock—Doxorubicin—testicular cancer	2.37e-05	0.00051	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—testicular cancer	2.36e-05	0.000508	CcSEcCtD
Topotecan—Fatigue—Methotrexate—testicular cancer	2.36e-05	0.000508	CcSEcCtD
Topotecan—Infection—Doxorubicin—testicular cancer	2.35e-05	0.000506	CcSEcCtD
Topotecan—Pain—Methotrexate—testicular cancer	2.34e-05	0.000503	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.33e-05	0.000502	CcSEcCtD
Topotecan—Nervous system disorder—Doxorubicin—testicular cancer	2.32e-05	0.0005	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—testicular cancer	2.32e-05	0.000499	CcSEcCtD
Topotecan—Skin disorder—Doxorubicin—testicular cancer	2.3e-05	0.000495	CcSEcCtD
Topotecan—Paraesthesia—Epirubicin—testicular cancer	2.3e-05	0.000495	CcSEcCtD
Topotecan—Hyperhidrosis—Doxorubicin—testicular cancer	2.29e-05	0.000493	CcSEcCtD
Topotecan—Dyspnoea—Epirubicin—testicular cancer	2.28e-05	0.000491	CcSEcCtD
Topotecan—Anorexia—Doxorubicin—testicular cancer	2.26e-05	0.000486	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—testicular cancer	2.25e-05	0.000485	CcSEcCtD
Topotecan—Dyspepsia—Epirubicin—testicular cancer	2.25e-05	0.000485	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—testicular cancer	2.23e-05	0.000481	CcSEcCtD
Topotecan—Decreased appetite—Epirubicin—testicular cancer	2.22e-05	0.000479	CcSEcCtD
Topotecan—Gastrointestinal disorder—Epirubicin—testicular cancer	2.21e-05	0.000476	CcSEcCtD
Topotecan—Fatigue—Epirubicin—testicular cancer	2.2e-05	0.000475	CcSEcCtD
Topotecan—Pain—Epirubicin—testicular cancer	2.19e-05	0.000471	CcSEcCtD
Topotecan—Constipation—Epirubicin—testicular cancer	2.19e-05	0.000471	CcSEcCtD
Topotecan—Urticaria—Methotrexate—testicular cancer	2.17e-05	0.000468	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—testicular cancer	2.16e-05	0.000465	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—testicular cancer	2.16e-05	0.000465	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.16e-05	0.000464	CcSEcCtD
Topotecan—Paraesthesia—Doxorubicin—testicular cancer	2.12e-05	0.000458	CcSEcCtD
Topotecan—Dyspnoea—Doxorubicin—testicular cancer	2.11e-05	0.000455	CcSEcCtD
Topotecan—Feeling abnormal—Epirubicin—testicular cancer	2.11e-05	0.000454	CcSEcCtD
Topotecan—Gastrointestinal pain—Epirubicin—testicular cancer	2.09e-05	0.000451	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—testicular cancer	2.08e-05	0.000449	CcSEcCtD
Topotecan—Decreased appetite—Doxorubicin—testicular cancer	2.06e-05	0.000443	CcSEcCtD
Topotecan—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.04e-05	0.00044	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—testicular cancer	2.04e-05	0.00044	CcSEcCtD
Topotecan—Urticaria—Epirubicin—testicular cancer	2.03e-05	0.000438	CcSEcCtD
Topotecan—Pain—Doxorubicin—testicular cancer	2.02e-05	0.000436	CcSEcCtD
Topotecan—Constipation—Doxorubicin—testicular cancer	2.02e-05	0.000436	CcSEcCtD
Topotecan—Abdominal pain—Epirubicin—testicular cancer	2.02e-05	0.000436	CcSEcCtD
Topotecan—Body temperature increased—Epirubicin—testicular cancer	2.02e-05	0.000436	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—testicular cancer	2.01e-05	0.000434	CcSEcCtD
Topotecan—Asthenia—Methotrexate—testicular cancer	1.96e-05	0.000422	CcSEcCtD
Topotecan—Feeling abnormal—Doxorubicin—testicular cancer	1.95e-05	0.00042	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—testicular cancer	1.93e-05	0.000417	CcSEcCtD
Topotecan—Pruritus—Methotrexate—testicular cancer	1.93e-05	0.000417	CcSEcCtD
Topotecan—Hypersensitivity—Epirubicin—testicular cancer	1.88e-05	0.000406	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—testicular cancer	1.88e-05	0.000405	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—testicular cancer	1.87e-05	0.000403	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—testicular cancer	1.87e-05	0.000403	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—testicular cancer	1.87e-05	0.000403	CcSEcCtD
Topotecan—Asthenia—Epirubicin—testicular cancer	1.83e-05	0.000395	CcSEcCtD
Topotecan—Pruritus—Epirubicin—testicular cancer	1.81e-05	0.00039	CcSEcCtD
Topotecan—Dizziness—Methotrexate—testicular cancer	1.81e-05	0.000389	CcSEcCtD
Topotecan—Diarrhoea—Epirubicin—testicular cancer	1.75e-05	0.000377	CcSEcCtD
Topotecan—Hypersensitivity—Doxorubicin—testicular cancer	1.74e-05	0.000376	CcSEcCtD
Topotecan—Vomiting—Methotrexate—testicular cancer	1.74e-05	0.000374	CcSEcCtD
Topotecan—Rash—Methotrexate—testicular cancer	1.72e-05	0.000371	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—testicular cancer	1.72e-05	0.000371	CcSEcCtD
Topotecan—Headache—Methotrexate—testicular cancer	1.71e-05	0.000369	CcSEcCtD
Topotecan—Asthenia—Doxorubicin—testicular cancer	1.7e-05	0.000366	CcSEcCtD
Topotecan—Dizziness—Epirubicin—testicular cancer	1.69e-05	0.000364	CcSEcCtD
Topotecan—Pruritus—Doxorubicin—testicular cancer	1.67e-05	0.000361	CcSEcCtD
Topotecan—Vomiting—Epirubicin—testicular cancer	1.63e-05	0.00035	CcSEcCtD
Topotecan—Nausea—Methotrexate—testicular cancer	1.62e-05	0.00035	CcSEcCtD
Topotecan—Diarrhoea—Doxorubicin—testicular cancer	1.62e-05	0.000349	CcSEcCtD
Topotecan—Rash—Epirubicin—testicular cancer	1.61e-05	0.000347	CcSEcCtD
Topotecan—Dermatitis—Epirubicin—testicular cancer	1.61e-05	0.000347	CcSEcCtD
Topotecan—Headache—Epirubicin—testicular cancer	1.6e-05	0.000345	CcSEcCtD
Topotecan—Dizziness—Doxorubicin—testicular cancer	1.56e-05	0.000337	CcSEcCtD
Topotecan—Nausea—Epirubicin—testicular cancer	1.52e-05	0.000327	CcSEcCtD
Topotecan—Vomiting—Doxorubicin—testicular cancer	1.5e-05	0.000324	CcSEcCtD
Topotecan—Rash—Doxorubicin—testicular cancer	1.49e-05	0.000321	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—testicular cancer	1.49e-05	0.000321	CcSEcCtD
Topotecan—Headache—Doxorubicin—testicular cancer	1.48e-05	0.000319	CcSEcCtD
Topotecan—Nausea—Doxorubicin—testicular cancer	1.41e-05	0.000303	CcSEcCtD
